EVGN Evogene

USD 0.74 0.01 0.698534
Icon

Evogene (EVGN) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.7352

+0.01 (+0.70)%

USD 0.04B

0.03M

USD 1.85(+151.63%)

N/A

Icon

EVGN

Evogene (USD)
COMMON STOCK | NSD
USD 0.74
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.04B

N/A

USD 0.74

Evogene (EVGN) Stock Forecast

USD 1.85
(+151.63%)

Based on the Evogene stock forecast from 1 analysts, the average analyst target price for Evogene is USD 1.85 over the next 12 months. Evogene’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Evogene is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Evogene’s stock price was USD 0.7352. Evogene’s stock price has changed by -8.13% over the past week, -16.93% over the past month and +22.53% over the last year.

No recent analyst target price found for Evogene
No recent average analyst rating found for Evogene

Company Overview Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platf...Read More

https://www.evogene.com

13 Gad Feinstein Street, Rehovot, Israel, 7414002

0

December

USD

USA

Adjusted Closing Price for Evogene (EVGN)

Loading...

Unadjusted Closing Price for Evogene (EVGN)

Loading...

Share Trading Volume for Evogene Shares

Loading...

Compare Performance of Evogene Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for EVGN

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Evogene (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO
Novo Nordisk A/S -1.36 (-1.05%) USD554.45B 46.01 4.80

ETFs Containing EVGN

Symbol Name EVGN's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Evogene (EVGN) Stock

Based on ratings from 1 analysts Evogene's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.

Unfortunately we do not have enough data on EVGN's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for EVGN is USD 1.85 over the next 12 months. The maximum analyst target price is USD 1.85 while the minimum anlayst target price is USD 1.85.

Unfortunately we do not have enough data on EVGN's stock to indicate if its overvalued.

The last closing price of EVGN's stock was USD 0.74.

The most recent market capitalization for EVGN is USD 0.04B.

Based on targets from 1 analysts, the average taret price for EVGN is projected at USD 1.85 over the next 12 months. This means that EVGN's stock price may go up by +151.63% over the next 12 months.

We can't find any ETFs which contains Evogene's stock.

As per our most recent records Evogene has 0 Employees.

Evogene's registered address is 13 Gad Feinstein Street, Rehovot, Israel, 7414002. You can get more information about it from Evogene's website at https://www.evogene.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...